1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Insulin Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of diabetes and obesity with increasing geriatric population
5.1.1.2. Rapid development in insulin delivery systems
5.1.1.3. Favorable reimbursement policies for insulin products in developed countries
5.1.2. Restraints
5.1.2.1. High cost associated with insulin drugs
5.1.3. Opportunities
5.1.3.1. Potential investments in R&D activities for insulin development
5.1.3.2. Rising approvals for interchangeable biosimilar insulin products
5.1.4. Challenges
5.1.4.1. Complex regulatory landscape and problems related to patient adherence to treatment regimens
5.2. Market Segmentation Analysis
5.2.1. Drug: Significant use of biologic drugs due to having safety, efficacy, and innovative features
5.2.2. Type: Long-acting insulins provide basal coverage for an extended duration
5.2.3. Application: Extensive use of insulin by type I diabetic patients requires constant monitoring and timely administration of insulin
5.3. Market Trend Analysis
5.3.1. Established healthcare infrastructure and development of affordable product have supplemented market growth across the Americas
5.3.2. Government support to increase accessibility and usage of insulin in APAC region
5.3.3. Research & development activities and availability of reimbursement policies for insulin in the EMEA region
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
6. Insulin Market, by Drug
6.1. Introduction
6.2. Biologic
6.3. Biosimilar
7. Insulin Market, by Type
7.1. Introduction
7.2. Intermediate-acting Insulin
7.3. Long-acting Insulin
7.4. Premixed Insulin
7.5. Rapid-acting Insulin
7.6. Short-acting Insulin
8. Insulin Market, by Application
8.1. Introduction
8.2. Type I Diabetes
8.3. Type II Diabetes
9. Americas Insulin Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Insulin Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Insulin Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Agreement, Collaboration, & Partnership
12.3.1.1. Gulf Pharmaceutical Industries ‘Julphar’ Signs Landmark Agreement with Sunshine Lake Pharma to Pioneer Insulin Biosimilar Manufacturing in MENA
12.3.1.2. California, Drugmaker Partner to Produce Affordable Insulin
12.3.1.3. ADOCIA Announces the Successful Phase 1 Study for BioChaperone Lispro with Partner Tonghua Dongbao
12.3.1.4. Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
12.3.1.5. Optum, Sanofi Partner on Low Cost Insulin for the Uninsured
12.3.2. New Product Launch & Enhancement
12.3.2.1. Sanofi Launches New Long-Acting Insulin Drug in India
12.3.2.2. Novo Nordisk to Launch Once-a-Week Insulin Regime for Indian Patients
12.3.2.3. Glenmark Launches Type 2 Diabetes and High Insulin Resistance Drug in India; Shares Jump
12.3.2.4. Novo Nordisk Launches Unbranded Biologic of Tresiba Analog Insulin to Expand Affordability Options for Patients
12.3.3. Investment & Funding
12.3.3.1. Insulin Maker GeneSys to Invest USD 50-60 MN to Set Up Plant in Hyderabad
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. ADOCIA
13.1.2. AstraZeneca PLC
13.1.3. Baxter International, Inc.
13.1.4. Biocon Limited
13.1.5. Bioton S.A.
13.1.6. CardioVends
13.1.7. Eli Lilly and Company
13.1.8. Eva Pharma
13.1.9. GeneSys Biologics
13.1.10. Glenmark Pharmaceuticals Ltd.
13.1.11. Gulf Pharmaceutical Industries (Julphar)
13.1.12. MannKind Corporation
13.1.13. Merck & Co., Inc.
13.1.14. MJ Biopharm Pvt. Ltd.
13.1.15. Novartis AG
13.1.16. Novo Nordisk A/S
13.1.17. Oramed Pharmaceuticals Inc.
13.1.18. Pfizer Inc.
13.1.19. Sanofi Group
13.1.20. Tonghua Dongbao Pharmaceutical Co., Ltd.
13.1.21. Viatris Inc.
13.1.22. Wockhardt Limited
13.1.23. Zealand Pharma A/S
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
